0 rating

Rivaroxaban in Hip and Knee Arthroplasty Surgery

Lars C Borris, MD

Rivaroxaban is a direct Factor Xa inhibitor that belongs to a new class of oral antithrombotic drugs. The drug has been on the market since 2008 and is now available in >100 countries around the world for thromboprophylaxis after total hip arthroplasty (THA) and total knee arthroplasty (TKA). Rivaroxaban is well tolerated, with a relatively short half-life and a high bioavailablity. The recommended prophylactic dosage is 10 mg once-daily started 6–10 h after surgery and continued for a total of 5 weeks after THA and 2 weeks after TKA. After THA, rivaroxaban for 5 weeks has been shown to be significantly more effective and equally safe compared with 5 weeks of enoxaparin 40 mg once-daily started the evening before surgery. After TKA, 2 weeks of treatment with rivaroxaban has been found to be more effective and equally safe compared with 2 weeks of enoxaparin 40 mg once-daily started the evening before surgery or 30 mg twice-daily started 12–24 h after surgery. The purpose of the present review is to critically evaluate the clinical profile of rivaroxaban based on data from the Phase IIb and Phase III clinical study programs from a practical orthopaedic point of view. Adv Orthop 2011;2(4):148–54.

Return to top

LATEST ARTICLES

Our most popular articles